DHODH’s expression or activity is increased in several cancers37 and in the last few years there has been growing interest about its potential as therapeutic target in cancers such as AML32, BRAF mutant melanoma38, triple negative breast cancers39 and PTEN mutant tumors40. The gene discussed is BRAF; the disease is cancer.